Scientific Publications by FDA Staff
J Pharm Sci 2013 Nov;102(11):3867-82
Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems.
Narang AS, Chang RK, Hussain MA
Pharmaceutical nanomaterials (NMs) encompass a wide variety of materials including drug nanoparticles (NPs), which can be amorphous or crystalline; or nanoparticulate drug delivery systems, such as micelles, microemulsions, liposomes, drug-polymer conjugates, and antibody-drug conjugates. These NMs are either transient or persistent-depending on whether the integrity of their structure and size is maintained until reaching the site of drug action. Examples of several approved drug products are included as pharmaceutical nanoparticulate systems along with a commentary on the current development issues and paradigms for various categories of NPs. This commentary discusses the preparation of nanoparticulate systems for commercial development, and the biopharmaceutical and pharmacokinetic advantages of these systems. A criterion of criticality is defined that incorporates the structure, in addition to size requirement of pharmaceutical NPs to identify systems that may require special development and regulatory considerations. (c) 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:3867-3882, 2013.
|Category: Journal Article|
|PubMed ID: #24037829||DOI: 10.1002/jps.23691|
|Includes FDA Authors from Scientific Area(s): Drugs|
|Entry Created: 2013-11-10|